Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Mar 01 04:00PM ET
14.80
Dollar change
+2.40
Percentage change
19.35
%
IndexRUT P/E- EPS (ttm)-2.32 Insider Own13.63% Shs Outstand55.10M Perf Week9.71%
Market Cap815.48M Forward P/E- EPS next Y-2.21 Insider Trans34.90% Shs Float47.59M Perf Month13.50%
Income-96.06M PEG- EPS next Q-0.49 Inst Own86.00% Short Float13.00% Perf Quarter12.29%
Sales0.00M P/S- EPS this Y18.99% Inst Trans-1.87% Short Ratio7.05 Perf Half Y58.63%
Book/sh5.04 P/B2.94 EPS next Y-4.36% ROA-36.61% Short Interest6.18M Perf Year269.08%
Cash/sh5.03 P/C2.95 EPS next 5Y- ROE-38.98% 52W Range3.00 - 17.79 Perf YTD5.49%
Dividend Est.- P/FCF- EPS past 5Y-158.58% ROI-34.70% 52W High-16.81% Beta2.14
Dividend TTM- Quick Ratio17.66 Sales past 5Y0.00% Gross Margin- 52W Low393.33% ATR (14)1.10
Dividend Ex-Date- Current Ratio17.66 EPS Y/Y TTM7.53% Oper. Margin0.00% RSI (14)56.70 Volatility6.61% 7.86%
Employees86 Debt/Eq0.01 Sales Y/Y TTM- Profit Margin- Recom1.12 Target Price24.43
Option/ShortYes / Yes LT Debt/Eq0.01 EPS Q/Q15.75% Payout- Rel Volume2.00 Prev Close12.40
Sales Surprise- EPS Surprise6.18% Sales Q/Q- EarningsNov 07 AMC Avg Volume877.36K Price14.80
SMA201.38% SMA5011.29% SMA20030.58% Trades Volume1,752,728 Change19.35%
Date Action Analyst Rating Change Price Target Change
Jan-30-24Initiated Citigroup Buy $20
Jul-21-23Initiated Oppenheimer Outperform $21
May-05-23Initiated CapitalOne Overweight $16
Feb-22-23Initiated Credit Suisse Outperform $12
Jul-06-22Resumed Canaccord Genuity Buy $16
Jun-09-22Upgrade H.C. Wainwright Neutral → Buy $12
Feb-28-22Initiated H.C. Wainwright Neutral
Dec-07-21Resumed Cowen Outperform
Dec-14-20Initiated JP Morgan Overweight $52
Dec-14-20Initiated Jefferies Buy $70
Feb-06-24 07:01AM
Feb-02-24 04:30PM
Jan-22-24 10:54AM
Jan-08-24 08:12AM
Jan-02-24 04:01PM
10:59AM Loading…
Dec-21-23 10:59AM
Dec-05-23 12:27PM
Dec-04-23 04:29PM
Dec-01-23 09:30AM
Nov-28-23 05:10PM
Nov-27-23 12:54PM
11:32AM
Nov-22-23 09:00AM
Nov-07-23 04:02PM
Nov-02-23 04:32PM
04:27PM Loading…
Nov-01-23 04:27PM
Oct-30-23 08:50AM
Oct-26-23 10:33AM
Oct-22-23 02:55AM
Oct-20-23 01:15PM
Oct-17-23 07:01AM
Oct-16-23 07:02AM
Oct-12-23 07:01AM
Oct-11-23 09:55AM
08:50AM
Oct-10-23 07:00AM
Oct-03-23 04:30PM
Sep-27-23 09:24PM
Sep-25-23 09:55AM
08:50AM
07:29AM Loading…
Sep-20-23 07:29AM
Sep-15-23 01:09PM
Sep-14-23 11:02PM
Sep-08-23 12:00PM
09:55AM
Sep-07-23 04:02PM
Sep-06-23 04:30PM
Sep-05-23 04:30PM
07:30AM
Aug-08-23 04:03PM
08:23AM
Aug-02-23 04:30PM
Aug-01-23 08:00AM
Jul-05-23 07:30AM
Jun-14-23 01:00PM
Jun-02-23 04:30PM
May-30-23 04:30PM
May-19-23 06:29AM
May-11-23 08:43AM
May-09-23 04:01PM
May-08-23 07:06AM
May-02-23 04:30PM
Apr-13-23 04:30PM
Apr-04-23 04:30PM
Mar-09-23 04:00PM
Mar-02-23 05:00PM
04:05PM
Feb-21-23 04:30PM
Feb-02-23 06:00PM
Jan-04-23 04:30PM
Jan-03-23 07:00AM
Jan-02-23 08:23AM
Dec-07-22 03:37PM
Dec-02-22 04:30PM
Nov-21-22 09:16AM
Nov-08-22 04:30PM
Nov-02-22 04:30PM
Nov-01-22 08:00AM
Oct-26-22 08:01AM
03:00AM
Oct-12-22 07:01AM
Oct-04-22 04:29PM
Sep-06-22 04:30PM
Sep-01-22 05:01PM
Aug-09-22 04:35PM
04:30PM
Aug-04-22 04:30PM
Aug-03-22 04:30PM
Jul-26-22 07:32AM
Jul-22-22 06:49AM
Jul-21-22 07:30AM
Jul-07-22 10:40AM
Jul-05-22 04:30PM
Jun-09-22 07:35AM
07:30AM
Jun-02-22 04:30PM
May-24-22 04:30PM
May-09-22 04:30PM
May-03-22 04:30PM
Apr-18-22 04:30PM
Apr-04-22 07:30AM
Mar-08-22 04:35PM
Feb-28-22 04:30PM
Feb-22-22 07:30AM
Feb-16-22 10:06AM
Feb-03-22 05:00PM
Jan-31-22 07:30AM
Jan-04-22 07:30AM
Dec-16-21 12:38PM
Dec-01-21 04:09PM
Olema Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its product candidate, OP-1250, is a novel oral therapy with combined activity as both a complete ER antagonist, or CERAN, and a selective ER degrader, or SERD, which is believed to drive deeper, more durable responses than existing therapies. The company was founded by Cyrus L. Harmon and Peter J. Kushner on August 7, 2006 and is headquartered in San Francisco, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Harmon CyrusDirectorFeb 01Sale15.565,00077,800871,283Feb 02 05:00 PM
Harmon CyrusDirectorJan 31Sale12.2325,000305,750876,283Feb 02 05:00 PM
Zojwalla NaseemCHIEF MEDICAL OFFICERJan 25Option Exercise7.0220,000140,40066,664Jan 29 07:30 AM
Kovacs Shane William CharlesCH. OPERATING & FINANCIAL OFF.Jan 12Option Exercise7.0250,000351,000484,987Jan 16 07:30 AM
Harmon CyrusDirectorDec 29Sale13.3825,000334,500901,283Jan 02 05:30 PM
Kovacs Shane William CharlesCH. OPERATING & FINANCIAL OFF.Dec 12Option Exercise7.0210,00070,200434,987Dec 12 05:55 PM
Zojwalla NaseemCHIEF MEDICAL OFFICERDec 11Option Exercise7.022,90020,35846,664Dec 12 05:55 PM
Zojwalla NaseemCHIEF MEDICAL OFFICERDec 06Option Exercise7.0213,10091,96243,764Dec 07 08:30 PM
Paradigm Biocapital Advisors L10% OwnerDec 06Buy11.60100,0001,160,0006,590,981Dec 08 04:19 PM
Graham G. WalmsleyDirectorDec 05Buy14.19131,8701,871,2801,800,000Dec 18 06:30 PM
Harmon CyrusDirectorNov 30Sale12.5725,000314,250926,283Dec 01 05:15 PM
Bohen SeanPRESIDENT AND CEONov 22Sale13.9027,932388,255144,925Nov 22 07:00 PM
Kovacs Shane William CharlesCH. OPERATING & FINANCIAL OFF.Nov 22Sale13.899,145127,024424,987Nov 22 07:00 PM
Zojwalla NaseemCHIEF MEDICAL OFFICERNov 22Sale13.897,09598,55030,664Nov 22 07:00 PM
Myles David C.CH. DISCOV. & NON-CLIN DEV OFFNov 22Sale13.896,65392,410574,099Nov 22 07:00 PM
Harmon CyrusDirectorNov 22Sale13.903,98955,447951,283Nov 22 07:00 PM
Bohen SeanPRESIDENT AND CEONov 21Sale14.8829,293435,879172,857Nov 22 07:00 PM
Kovacs Shane William CharlesCH. OPERATING & FINANCIAL OFF.Nov 21Sale14.869,597142,632434,132Nov 22 07:00 PM
Zojwalla NaseemCHIEF MEDICAL OFFICERNov 21Sale14.847,461110,74737,759Nov 22 07:00 PM
Myles David C.CH. DISCOV. & NON-CLIN DEV OFFNov 21Sale14.886,976103,823580,752Nov 22 07:00 PM
Harmon CyrusDirectorNov 21Sale14.864,19262,293955,272Nov 22 07:00 PM
Myles David C.CH. DISCOV. & NON-CLIN DEV OFFNov 08Sale17.612003,522561,270Nov 13 05:30 PM
Myles David C.CH. DISCOV. & NON-CLIN DEV OFFNov 03Sale17.515419,473561,470Nov 03 09:39 PM
Harmon CyrusDirectorNov 02Sale15.645,00078,200943,714Nov 02 08:50 PM
Myles David C.CH. DISCOV. & NON-CLIN DEV OFFNov 02Sale15.363,33251,180562,011Nov 03 09:39 PM
Myles David C.CH. DISCOV. & NON-CLIN DEV OFFNov 01Sale15.026,668100,153565,343Nov 03 09:39 PM
Harmon CyrusDirectorOct 31Sale12.0525,000301,250948,714Nov 02 08:50 PM
Harmon CyrusDirectorSep 29Sale12.4125,000310,250973,714Oct 03 05:00 PM
Myles David C.CH. DISCOV. & NON-CLIN DEV OFFSep 19Sale12.6720,000253,400572,011Sep 21 05:00 PM
BVF PARTNERS L P/ILDirectorSep 12Buy9.841,505,93214,818,3714,688,954Sep 14 04:25 PM
Graham G. WalmsleyDirectorSep 12Buy9.84508,1304,999,9991,668,130Dec 18 06:30 PM
Harmon CyrusDirectorSep 05Sale11.6210,000116,200998,714Sep 05 09:08 PM
Harmon CyrusDirectorAug 31Sale9.3615,000140,4001,008,714Sep 05 09:08 PM
Harmon CyrusDirectorAug 16Sale10.1415,000152,1001,023,714Aug 17 05:00 PM
Harmon CyrusDirectorJun 08Sale6.3010,00063,0001,038,714Jun 09 05:30 PM
Harmon CyrusDirectorJun 06Sale6.295,00031,4751,048,714Jun 07 09:30 PM
Harmon CyrusDirectorJun 05Sale6.045,00030,2251,053,714Jun 07 09:30 PM